Lung Adenocarcinoma Clinical Trial
Official title:
Comparison of 18F-FDG and 68Ga-FAPI PET/CT in Patients With Lung Adenocarcinoma
To evaluate the potential usefulness of 68Ga-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in lung adenocarcinoma, compared with 18F-FDG PET/CT.
Participants with lung adenocarcinoma underwent contemporaneous 18F-FDG and 68Ga-FAPI PET/CT for an initial assessment. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FDG and 68Ga-FAPI PET/CT were calculated and compared to evaluate the diagnostic efficacy. In addition, the investigators further investigate the performance of 68Ga-FAPI PET/CT for differentiating invasive adenocarcinoma from adenocarcinoma in situ (pre-invasive lesion) or minimally invasive adenocarcinoma in participants with solitary ground-glass opacity nodules. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02898857 -
Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma
|
N/A | |
| Completed |
NCT02127359 -
Whole-Exome Sequencing (WES) of Cancer Patients
|
||
| Recruiting |
NCT01249066 -
Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
|
N/A | |
| Not yet recruiting |
NCT04482829 -
TCM in the Treatment of Lung Adenocarcinoma
|
N/A | |
| Recruiting |
NCT04929041 -
Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
|
Phase 2/Phase 3 | |
| Terminated |
NCT04691375 -
A Study of PY314 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT02621333 -
Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT02282267 -
Blood Detection of EGFR Mutation For Iressa Treatment
|
N/A | |
| Not yet recruiting |
NCT01942629 -
Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas
|
N/A | |
| Recruiting |
NCT01482585 -
Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
|
N/A | |
| Recruiting |
NCT03376737 -
Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT05537922 -
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
|
||
| Recruiting |
NCT04937283 -
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
|
N/A | |
| Recruiting |
NCT06255197 -
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
|
||
| Completed |
NCT02093000 -
A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma
|
N/A | |
| Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma
|
Phase 1 | |
| Terminated |
NCT04682431 -
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05736991 -
Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
|
||
| Enrolling by invitation |
NCT05136014 -
Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model
|
||
| Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 |